IO Frontiers World 2019


Pascal Touchon

Dr Pascal Touchon

SVP Global Head Cell & Gene, Novartis Oncology, Novartis

Pascal Touchon is Global Head, Oncology Strategy & Business Development. In this role, he is responsible for the development & execution of our strategy, portfolio management, BD&L, external collaborations and alliance management. Pascal was previously Senior Executive Vice President and Head of Business Development and Licensing for Servier, a private research-based pharmaceutical company, where he led the sourcing, evaluation, negotiation and closing numerous partnerships with biotechs, pharmaceutical companies and academic institutes. He has held positions in Research, Marketing and Sales, General Management and Business Development at various companies including Sanofi, Virbac, Glaxo, Glaxo-Wellcome and Servier. He has extensive international experience in managing marketing and commercial operations and as managing director in France, Central & Eastern Europe, Northern Europe, Asia, Australia, Canada, and South Africa.

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy